Capstone Partners advised Pregistry — a global leader in safety studies during pregnancy — on its sale to CorEvitas, a portfolio company of Audax.
Founded in 2014, Pregistry leverages the expertise of over 75 pregnancy specialists covering a range of clinical, safety, regulatory, marketing, and technology needs to provide information that supports healthy pregnancies and births. Pregistry partners with global pharmaceutical and biotechnology companies to conduct observational studies on drug and vaccine safety during pregnancy. The company’s data informs individuals, providers, and industry stakeholders regarding health and safety during and after pregnancy, and ensures that prescribers, regulators, and pharmaceutical companies have the information needed to understand the potential benefits and risks of medications and vaccines during pregnancy.
“For the last eight years, Pregistry has been a leader in the design and execution of FDA- and EMA-mandated pregnancy exposure registries and other observational studies in the maternal health field, including the world’s largest pregnancy registries on COVID-19 vaccines and COVID-19 treatments” said Dr. Diego Wyszynski, Founder and CEO of Pregistry. “Now, with CorEvitas’ investment and partnership, our teams will be able to provide deeper clinical registry data, a holistic view of the pregnant person’s experience, and deeper resources to our customers. Pregnant people and healthcare providers will have access to more information, allowing better treatment decisions and healthier pregnancies and babies.”
We were impressed by Pregistry’s data analytics capabilities and are certain that the combination with CorEvitas will provide an even broader platform for Pregistry to provide unique information and insights on the health of pregnant women across the globe.
“We are excited to partner with Dr. Diego Wyszynski and his team as we embark together on the next stage of expansion into syndicated pregnancy registries and leverage our companies’ collective resources, novel technology platforms, and deep patient insights to better serve our pharmaceutical customers,” said Raymond H. Hill, Chairman of the Board and CEO at CorEvitas. “Pregistry conducts pregnancy studies required by regulatory agencies worldwide, complementing our existing pharmacovigilance business while opening a new set of use cases for CorEvitas to serve.”
CorEvitas’ acquisition of Pregistry accelerates the company’s continued expansion of syndicated registries, complementing its already deep base of expertise in conducting post-approval safety studies in autoimmune and inflammatory-mediated diseases. CorEvitas brings 20 years of experience creating and managing specialized patient registries to study real-world effectiveness and safety of advanced therapies.
CorEvitas is headquartered in Waltham, MA and is a portfolio company of Audax Private Equity. CorEvitas is a science-led, real-world data intelligence company. Using syndicated registry data and analytic services to understand the post-approval comparative effectiveness and safety of approved therapies, The company provides biopharmaceutical companies with objective data and clinical insights to demonstrate the value of their products to clinicians, patients, payers, and regulators.
Audax Group is a leading alternative investment manager with offices in Boston, New York, San Francisco and London. Since its founding in 1999, Audax has raised over $32 billion in capital across its Private Equity and Private Debt businesses.
The expert investment banking professionals on Capstone Partners’ Healthcare Information Technology Team work with leading middle market companies operating in the Healthcare IT market to advise with their strategic decision-making in order to maximize financial outcomes at every stage of the business lifecycle. Our firm has developed a full suite of corporate finance solutions, including M&A advisory, debt advisory, financial advisory, and equity capital financing to help privately owned businesses and private equity firms address any need, ranging from growth and financial or operational advisement to an ultimate exit transaction. To learn more about this transaction, or about the benefits of starting a relationship with our Technology Banking Team, contact us here.